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Abstract
All living organisms exhibit autonomous daily physiological and behavioural rhythms to help them synchronize with the
environment. Entrainment of circadian rhythm is achieved via activation of cyclic AMP (cAMP) and mitogen-activated
protein kinase signaling pathways. NonO (p54nrb) is a multifunctional protein involved in transcriptional activation of the
cAMP pathway and is involved in circadian rhythm control. Rasd1 is a monomeric G protein implicated to play a pivotal role
in potentiating both photic and nonphotic responses of the circadian rhythm. In this study, we have identified and validated
NonO as an interacting partner of Rasd1 via affinity pulldown, co-immunoprecipitation and indirect immunofluorescence
studies. The GTP-hydrolysis activity of Rasd1 is required for the functional interaction. Functional interaction of Rasd1-NonO
in the cAMP pathway was investigated via reporter gene assays, chromatin immunoprecipitation and gene knockdown. We
showed that Rasd1 and NonO interact at the CRE-site of specific target genes. These findings reveal a novel mechanism by
which the coregulator activity of NonO can be modulated.
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Introduction
The cAMP-dependent pathway is known to respond to
information obtained from numerous extracellular stimuli to
regulate processes including synaptic plasticity, neuronal differen-
tiation, circadian rhythm, memory, and glucose homeostasis
[1,2,3,4,5,6]. Despite the involvement of unique neurotransmitters,
hormones or other signals, and different intracellular signaling
systems, these pathways all converge at the nucleus. Hence,
specificity of the signal and the pathway induced is crucial to
ensure that specific proteins are transcribed to perform precise
functions in a tissue- and/or temporal-specific manner. This
specificity is achieved by the type of signals, how the signals are
detected and relayed to specific signaling proteins responding to the
stimuli, and the subsequent interactions with other proteins, and is
dependent on cell type and contexts. Regulation of the pathway can
occur at any step of the signal transduction process but one of
the more prominent regulations is at the transcriptional level.
Regulation of the pathway at the transcriptional level is achieved by
various mechanisms including inhibition of core transcription factor
activity, sequestration, and competition for limiting factor [7,8,9].
NonO is predominantly localized in the paraspeckles [10], a
sub-compartment of the nucleus, and is a member of the family of
RNA-Recognition Motif (RRM) containing proteins [11]. NonO
is a co-activator of CREB and has been known to serve in both
transcriptional activation and repression [12,13,14,15]. In our
current study, NonO is identified as a binding partner of Rasd1, a
monomeric G protein belonging to the RAS family [16,17].
Traditionally, RAS proteins function as cytoplasmic signal transducers
of diverse intracellular signaling pathways including the cAMP-
dependent pathway [16]. Similar to its other family members,
Rasd1 harbours a CAAX motif at its C-terminal and displays a high
degree of conservation in its G boxes, which are responsible for the
guanine nucleotide binding and hydrolysis activities of RAS
proteins. Mutations in the G boxes have been shown to disrupt
the functions of RAS proteins [16,18,19,20,21,22,23,24]. Rasd1 has
been shown in various studies to be involved as signal transducers of
multiple signaling pathways, including iron homeostasis, growth
hormone secretion and circadian rhythm [20,25,26,27,28,29].
Recently, Rasd1 has also been observed to reside in the nucleus,
serving as a transcriptional repressor of glycogen synthase kinase 3b
[19] as well as an inhibitor of the cAMP-dependent pathway
[20,28,29].
In this study, we identify NonO as a novel binding partner of
Rasd1. This is the first study that shows the novel interaction
of a RRM-possessing protein with a monomeric G protein. In the
nucleus, Rasd1 binds to NonO and regulates the cAMP-dependent
pathway at the transcriptional level. GTP-hydrolysis activity of
Rasd1 is required for repressing CREB activity. We propose a
new mechanism of regulating the cAMP-dependent pathway at the
transcriptional level via modulation of the co-activator’s function.
Binding of Rasd1 to NonO modulates NonO’s functions by
changing NonO from a co-activator to a co-repressor of the cAMP-
dependent pathway. Rasd1 and NonO cooperate to suppress the
transcription of a subset of CRE-containing genes, NR4A 1 & 2.
This finding adds weight to how specificity of signaling pathways is
achieved via the usage of different interacting partners to modulate
the function of a multi-tasking co-regulator [30].
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NonO was identified as a novel interacting partner of
Rasd1 via affinity pull-down assay followed by mass
spectrometry analysis
To facilitate our understanding of Rasd1’s physiological
functions, an in vitro affinity assay was performed to identify novel
interacting partners of Rasd1. COS-7 cells were used to over-
express His-Rasd1 for subsequent interaction studies. The His-
tagged proteins were then purified by Ni-NTA magnetic beads.
This was followed by incubation with cell lysate extracted from
PC-12 cells, which are known to express endogenous Rasd1 [26].
The complexes bound to Rasd1 were eluted and fractionated by
SDS-PAGE. Three distinct bands were observed on the elute lane
of beads bound with His-Rasd1 but not in the elute lane of
negative control (compare Figure 1A, Lanes 1 with 5). These
bands were excised, and mass spectrometry was conducted to
determine the identity of the proteins. The band that was approx-
imately 30 kDa on the gel (Figure 1A, Lane 5) was identified to be
Rasd1. It was logical that the band was present in the elute lane for
cells transfected with pHis-Rasd1 but not in the negative control.
The next two bands at approximately 50 kDa and 55 kDa on
Lane 5 were analysed with mass spectrometry as well. The bands
were identified as Tubb5 and NonO, respectively (Figure 1A,
Lane 5). In the present study, we focused exclusively on
investigating the interaction between NonO and Rasd1.
In vivo interaction study confirms NonO as a novel
binding partner of Rasd1
To validate the interaction between Rasd1 and NonO, an in vivo
interaction study was conducted by co-transfecting COS-7 cells
with plasmids expressing either HA-Rasd1 and GST-NonO or
HA-Rasd1 and GST. GST and GST-tagged proteins were
purified with MagneGST
TM particles. Bound complexes were
eluted and then fractionated on SDS-PAGE, followed by western
blot. GST-NonO was observed to co-precipitate HA-Rasd1
specifically (Figure 1B, Lane 2). A similar observation was
observed when cells were co-transfected with pGST-Rasd1 and
pNonO-V5. In this case, GST-Rasd1 was purified using GSH-
linked beads, and NonO-V5 was co-precipitated along with GST-
Rasd1 (Figure 1C, Lane 2). Previous studies have shown that
Rasd1 and NonO are expressed in HEK293T cells [13,26]; hence
co-IP was carried out using HEK293T cell lysates. An antibody
against NONO was used to precipitate endogenous NONO,
and RASD1 was observed to be co-precipitated with NONO
(Figure 1D, Lane 2). In addition, co-IP using mouse brain lysate
was also performed. Rasd1 was purified by anti-Rasd1 and NonO
was observed to co-purify specifically with Rasd1 (Figure 1E, Lane
2). The results obtained from co-precipitation and co-IP assays
show that interaction of Rasd1 and NonO is specific and
conserved across species (mouse and human).
Rasd1 interacts with NonO to suppress CREB-mediated
transcription
Rasd1 protein has been shown to play multiple roles in the
regulation of the cAMP pathway, including heterologous sensitisa-
tion of adenylyl cyclase 1 via Gbc, attenuation of cAMP-stimulated
hGH secretion, and inhibition of adenylyl cyclase through Gia in the
HEK293T cell line [20,28,29]. Similar involvement was shown for
NonO in the cAMP pathway. NonO interacts with TORC2
(transducer of regulated CREB-binding proteins 2) and functions as
a co-activator to upregulate transcription of NR4A2 and FOS upon
activation of the cAMP-dependent pathway; it has also been shown
to be involved in regulation of CYP179s transcription via this
pathway [13,14]. In this paper, we employed the PathDetect CREB
trans-Reporting System to investigate the effects of Rasd1 and
NonO on CREB-mediated gene transcription in HEK293T cells.
Cells were transfected with pHis-Rasd1 along with luciferase
reporter gene driven by CREB-responsive promoter and CREB-
expressing vector. Prior to harvest, cells were induced with forskolin
for 4 hours to study the effect of Rasd1 on the cAMP pathway. We
observed that Rasd1 repressed the CREB-mediated transcription in
a dose-dependent manner (compare Figure 2A, bars I with II–IV),
supporting the findings reported in the previous study [19]. We
transfected plasmid-expressing NonO in HEK293T cells to observe
the effect of NonO on CREB’s activity via reporter gene assay.
Transfection of NonO in the cells onlyled to a mild activation of the
CREB-luciferase reported activity (compare Figure 2B, bars I
with V).
When plasmids expressing NonO and Rasd1 were co-
transfected in HEK293T cells to study the effect of these proteins
on the pathway, the CREB-luciferase reporter activity was
reduced by 80% (compare Figure 2B, bars I and VIII). The up-
regulation effect of NonO on the pathway was also abolished in
the presence of Rasd1 (compare Figure 2B, bars V with VIII). In
addition, the repressive effect of Rasd1 on the pathway was
enhanced in the presence of NonO (compare Figure 2A, bar IV
with Figure 2B, bar VIII). These results suggest that Rasd1 acts as
a regulator of NonO to modulate its function in transcription.
Rasd1 and NonO co-localise in the nucleus
Co-localisation studies were performed by co-transfection of
Rasd1- and NonO- expressing plasmids to study if Rasd1 and
NonO influence each other’s sub-cellular localisation. Consistent
with previous reports, we observed that in cells transfected with
pNonO-V5, NonO mainly resides in the nucleus (Figure 3, A2)
[12,13,14,15,31,32,33]. In addition, the localization of NonO was
not affected by the presence of Rasd1 (Figures 3, A2 & A9). On the
other hand, Rasd1 was distributed throughout the cells transfected
with pHis-Rasd1 (Figure 3, A5), which is consistent with previous
reports [19,34]. In the event of co-transfection of pGST-NonO
and pHis-Rasd1, a substantial increase in the nuclear localisation
of Rasd1 was observed when compared with transfection with
Rasd1 expression vector alone (compare Figures 3, A5 and A8).
The finding suggests that nuclear presence of Rasd1 is enhanced
by NonO.
GTP hydrolysis activity of Rasd1 is required for repression
of CREB-mediated transcription
As a member of the monomeric G protein family, Rasd1
possesses GTP binding and hydrolysis activity. RAS proteins are
activated when GTP-bound and inactivated when GDP-bound. In
order to obtain a better understanding of the mechanism by which
the cooperation of Rasd1 with NonO mediates a suppressive
effect, three Rasd1 mutants with point mutations of the conserved
residues at the G boxes of RAS proteins were constructed.
The mutants consist of two constitutively active mutants of Rasd1
– A178V and G81A – and an inactive mutant, T38N. Simi-
lar Rasd1 mutants have been constructed, including H-Ras
(H-Ras[A146V] and H-Ras[G60A]), and Rab11 (Rab11[S25N]
and Rab11[Q70L]) [21,22,34,35]. The A178V mutation is
expected to interrupt the guanyl nucleotide-binding pocket,
resulting in an enhanced exchange rate of guanine nucleotides
[20,35]. Since, guanyl nucleotide exchange is the rate limiting step
in the activation of G proteins, and the intracellular levels of GTP
is higher than GDP, an increase in the nucleotide exchange rate is
supposed to lead to an increased occupancy in the active
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GTP to GDP in vivo and behave functionally as constitutively
active signal transducers [20,35]. However, the mutant has an
overall lower activity than the wild type. G81A, another con-
stitutively active mutant of Rasd1, carries a point mutation in the
G3 box guanine residue. This mutation in H-Ras has been shown
to interfere with its interaction with GTPase-activating proteins
(GAPs), thus leading to a protein that is consistently bound to GTP
[21]. In the T38N mutant, the key residue in the G2 box is
switched from threonine to asparagine. This mutation is known to
severely reduce the binding affinity of Rab11 to GTP, leaving the
GDP-binding properties unchanged [22]. Therefore, the mutation
results in an inactive Rasd1 that is constantly bound to GDP. In a
previous study [19], it was suggested that a putative nuclear
translocation signal (NLS) on the C-terminal of Rasd1 permitted
its nuclear translocation. Hence, we constructed a Rasd1 mutant,
Del-NLS, in which the putative nuclear localisation signal was
deleted, to further understand how increased nuclear presence of
Rasd1 occurs in the company of NonO.
We observed from our immunofluorescence study that,
although all mutants (Figure 3A, 12, 19, 26 and 33) displayed
similar sub-cellular distribution as wild-type Rasd1 (Figure 3A, 5),
none of them displayed an increase in nuclear distribution upon
co-transfection with pGST-NonO (Figures 3A: 15, 22, 29, and 36).
Interestingly, NonO was observed in the cytoplasm upon co-
transfection with T38N (Figure 3A, 30), unlike all other co-
transfections where the sub-cellular location of NonO was
observed primarily in the nucleus (Figures 3A, 9, 16, 23, and 37).
Next, we compared the ability of wild-type and mutant Rasd1
to suppress CREB-mediated transcriptional activity in HEK293T
cells overexpressing NonO. We observed that none of the Rasd1
mutants were able to effectively suppress CREB-mediated tran-
scriptional activity when compared to the wild-type Rasd1
(compare Figure 3B, bars III with IV–VII). Interaction studies
were subsequently performed, and the results show that mutants
G81A and Del-NLS wereunable to interact with NonO (Figure 3C,
lanes 4 and 6); however, A178V and T38N werestill able to interact
with NonO (Figure 3C, lanes 3 and 5), and a substantial amount of
NonO was present in the cytoplasm (Figure 3C, 38) in the presence
of T38N. Taken together our findings suggest that interaction
between NonO and wild-type Rasd1 is required for the suppression
of CREB-mediated transcription.
Rasd1 cooperates with full-length NonO to repress CREB
activity
To map the interaction domain between Rasd1 and NonO, a
series of truncated NonO were constructed to determine the site at
which Rasd1 binds (Figure 4A). HEK293T cells were co-
transfected with pGST-Rasd1 and various plasmids containing
truncated NonO. GST-pulldown was performed using cell lysate
prepared from HEK293T cells transfected with the respective
plasmids. All truncated constructs except NonOD2 were able to
interact with Rasd1 (Figure 4B). Unlike other constructs which
possessed at least one RRM domain, there was no RRM domain
present in NonOD2. The results suggest that one RRM domain is
sufficient for interaction with Rasd1. Next, pGST-Rasd1 was co-
transfected with either NonOD1- or NonOD2-expressing plas-
mids to determine if the RRM domains (NonOD1) are adequate
for cooperation with Rasd1 to repress CREB’s activity. We
observed that, unlike wild-type NonO, neither truncated clones
were able to repress CREB’s activity in the presence of Rasd1
(compare Figure 4C, bars II with III and IV). This implies that
both the RRMs and the DNA-binding region of NonO were
required for functional interaction between Rasd1 and NonO.
Next, we investigated if the RRM domains of NonO are
responsible for the increased nuclear distribution of Rasd1 in the
presence of NonO via immunofluorescence studies. The NonOD1
construct lacking the nuclear localisation motif was unable to
translocate into the nucleus (Figure 4D2). In the event of co-
transfection of NonOD1 with Rasd1, Rasd1 was present only in
the cytoplasm, which is different in comparison to co-transfection
of NonO with Rasd1 (compare Figure 3C2 with Figure 4D5). The
results suggest that NonO may play a role in retaining Rasd1 in
the nucleus and that the nuclear presence of both NonO and
Rasd1 is required for down-regulating CREB-mediated transcrip-
tional activity (Figure 4C, bar III).
NR4A1 and NR4A2 are target genes regulated by both
Rasd1 and NonO in the cAMP pathway
Expression of both Rasd1 and NonO leads to the repression of
CREB-mediated transcriptional activity (Figure 2B, bar VIII). To
identify endogenous genes regulated by the combined actions of
both Rasd1 and NonO, plasmids expressing Rasd1 and NonO
were co-transfected into HEK293T cells. This was followed by
quantitative Real time PCR to study the transcriptional activity of
endogenous genes regulated by the cAMP pathway.
Several endogenous genes known to have a functional CRE site
were studied. This includes PER1 (Period1), CYP17, NR4A1,
NR4A2, NR4A3, FOS, and Prolyl-4-hydroxylase a 1 (Prolyl a).
However, out of all the genes studied in HEK293 cells, only the
transcript levels of NR4A1, NR4A2 and FOS were consistently
induced by forskolin (Figure S1). It has previously been shown that
not all genes that contain CRE elements (such as PEPCK, BDNF,
and insulin) are regulated by CREB in PC-12 cells [36]. Hence, our
Figure 1. NonO is identified as a novel interacting partner of Rasd1 via affinity pull-down assay. (A) Coomassie blue stained SDS-PAGE
gel of affinity pulldown assay. Ni-NTA magnetic beads were incubated either with lysate from pHis-Rasd1 transfected COS-7 cells or with lysate of
empty vector transfected cells. Next, washes were conducted to remove non-specific binding proteins. His-Rasd1 bound to the magnetic beads was
then incubated with PC-12 lysate. The beads were boiled to separate the protein complexes for fractionation on SDS-PAGE (12%). The 55 kDa, 50 kDa
and 30 kDa bands were observed in the elute lane of His-Rasd1 (Lane 5) but not in the elute lane of the negative control (Lane 1). Protein bands were
excised for further analysis using mass spectrometry. The proteins identified were NonO, Tubulin beta 5 and Rasd1, respectively. E, elute; W, wash;
and I, input. (B) Co-precipitation assay was performed to study in vivo interaction between Rasd1 and NonO. COS-7 cells were co-transfected with
plasmids expressing HA-Rasd1 and either GST-NonO or GST. The lysates were then incubated with GSH-linked magnetic beads to precipitate GST-
tagged proteins. HA-Rasd1 was observed to co-precipitate specifically with GST-NonO but not GST (compare Lanes 1 with 2). (C) A similar interaction
assay was performed for NonO-V5 and GST-Rasd1 proteins. In this experiment, COS-7 cells were co-transfected with pNonO-V5 and either pGST-
Rasd1 or pXJGST. GSH-linked magnetic beads were added to the cell lysates to pull-down GST-tagged proteins. NonO-V5 was observed to be co-
precipitated with GST-Rasd1 but not with GST (compare Lanes 1 with 2). (D) To study the in vivo interaction of endogenous Rasd1 and NonO, co-IP
was performed on HEK293T cell lysates incubated with either rabbit anti-NonO or rabbit control IgG. Detection of the blot with anti-Rasd1 showed
that RASD1 was co-IP specifically by NONO (Lane 2). (E) A similar Co-IP was conducted using mouse brain lysate incubated with either anti-Rasd1 or
goat control IgG. NonO was only co-precipitated by lysate incubated with anti-Rasd1 (Lane 2). NonO-V5 is detected with anti-V5 (Invitrogen, USA, CA);
GST-tagged proteins are detected with anti-GST (Santa Cruz, USA, CA); HA-Rasd1 is detected with anti-Xpress (Invitrogen, USA, CA); endogenous
NonO is detected with goat anti-NONO; and endogenous Rasd1 is detected with goat anti-Rasd1.
doi:10.1371/journal.pone.0024401.g001
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cohort of CRE-containing promoters in different cell lines,
perhaps due to a difference in the expression of co-regulators.
Therefore, in subsequent studies conducted with HEK293T cells,
we focus on the effect of NonO and Rasd1 on the transcription of
the endogenous NR4A1, NR4A2 and FOS.
We observed that induction of NR4A1 and NR4A2 gene
expression by forskolin was abolished upon co-transfection of
pNonO-V5 and pGST-Rasd1 (compare Figure 5A, bars II and
IV, for the respective genes). However, the induction of FOS gene
expression by forskolin was not affected by the presence of NonO
and Rasd1 (compare Figure 5A, bars IV of FOS, NR4A1 and
NR4A2). These results suggest that Rasd1 and NonO regulate a
subset of the CREB target genes in HEK293T cells. The
expression of negative control YWHAH was not affected by Rasd1
and NonO and/or forskolin (Figure 5A, bars I–IV).
To determine if Rasd1 is able to regulate transcription of CREB
target genes on its own, we performed experiments to knockdown
endogenous NONO in HEK293T cells. NONO-knockdown was able
to reduce the transcriptional activity of CREB target genes to levels
comparable to that observed in uninduced HEK293 cells (compare
Figure 5B, bars I with III of each gene). Transcription levels of these
genes were restored to levels similar to that in cells induced with
forskolin alone when NONO-knockdown cells were transfected with
NonO-expressing plasmid (compare Figure 5B, bars III with IV of
each gene), suggesting that NonO has a direct effect on the
regulation of genes containing the CRE-responsive element. pGST-
Rasd1 was transfected in NONO-knockdown HEK293T cells, and
the presence of Rasd1 had no effect on the transcript levels of the
CREB target genes (compare Figure 5B, bars III with V). These
results suggest that Rasd1 requires NonO to regulate the
transcription of CREB target genes. Next, we investigated the
influence of over-expression of Rasd1 and NonO on the
transcriptional regulation of NR4A1, FOS and NR4A2 in NONO-
knockdown cells. A similar trend to the results in Figure 5A, bar IV,
was observed upon co-transfection of Rasd1- and NonO-expressing
plasmids in NONO-knockdown cells (Figure 5B, bar VI of NR4A1
and NR4A2). Expression levels of FOS remained unaffected by the
presence of Rasd1 (compare Figure 5B, bars VI of FOS with NR4A1
and NR4A2). Hence, Rasd1 and NonO cooperate to regulate a
subset of CREB target genes including NR4A1 and NR4A2.
Physical presence of Rasd1 and NonO at the CRE-site of
NR4A2 promoter is required for repression of NR4A2
transcription
ChIP was carried out using forskolin-induced HEK293T lysates
transfected with pGST-Rasd1. Anti-NONO was incubated with
the lysates, and PCR was performed on the chromatin co-
immunoprecipitated along with NONO. Compared to cells
transfected with pGST (negative control), there was an increase
in the amount of NONO bound to the CRE-site of the NR4A2
promoter only in cell lysates transfected with pGST-Rasd1
(compare Figure 5C, Lanes 2 and 3). A similar experiment was
conducted on HEK293T cells transfected with either pHis-Rasd1
or pHis-Del-NLS (mutant that does not interact with NonO to
serve as negative control) to determine if increased binding of
NONO to the NR4A2 promoter could be due to the presence of
Rasd1 at the target promoter. Neither Rasd1 nor the mutant, Del-
NLS, was observed to be at the CRE-site of the FOS promoter
(Figure 5D, Lanes 5 and 6). This seemed reasonable, as Rasd1 was
unable to work with NonO to suppress the transcription of FOS.I n
the case of the NR4A2 promoter, only Rasd1 was able to co-
immunoprecipitate the NR4A2 promoter (Figure 5D, Lane 2). The
results suggest that binding of Rasd1and NonO to the CRE-site
of the NR4A2 promoter is required for the repression of its
transcription.
Discussion
In this study, we have identified NonO as a novel binding
partner of Rasd1 via in vitro affinity-based assay, and this
interaction is validated using pulldown and co-immunoprecipita-
tion assays. We then studied the roles of Rasd1 and NonO in the
cAMP pathway. Our findings show that co-localisation of Rasd1
and NonO in the nucleus is associated with the repression of a
subset of CREB target genes. This process involves the GTP
hydrolysis activity of Rasd1 and requires interaction of Rasd1 with
full-length NonO at the CRE-site of the target promoter. We
propose that Rasd1 modulates the function of NonO to down-
regulate CREB target genes, NR4A1 and NR4A2.
Our results show that deletion of the putative bipartite nuclear
localisation sequence located at the C-terminal portion of Rasd1
does not deter Rasd1 from entering the nucleus, implying that
Rasd1 enters the nucleus by other means. Small molecular weight
proteins of less than 60 kDa or 9 nm in diameter are able to enter
the nucleus via the nuclear pore complex by passive diffusion [37],
which is one possible mechanism employed by Rasd1, whose
molecular weight is 32 kDa, to enter the nucleus. NonO contains a
bipartite nuclear localisation signal, and Rasd1 may bind to NonO
to facilitate its entry into the nucleus. Our results indicated that the
lack of NonO’s NLS prevented accumulation of Rasd1 in the
nucleus, which suggests that NonO may play a role in retaining
Rasd1 in the nucleus. In addition, studies using Rasd1 mutants
show that GDP-bound Rasd1 resulted in cytoplasmic localisation
of NonO. This implies that nuclear retention of Rasd1 by NonO is
Figure 2. Effects of Rasd1 and NonO in the cAMP-signaling pathway in HEK293T cells were studied using reporter gene assay. (A)
NonO- (2 mg) and Rasd1- (or Rasd1 mutants) (2 mg) expressing plasmids were co-transfected in HEK293T cells. Immunofluorescence was performed 2
days after transfection. Cells were transfected with different amounts of His-Rasd1-expressing vector (0, 0.5, 1 and 2 mg) along with reporter vector
and CREB-expression vector. Two days later, cells were induced with forskolin (20 mM) for 4 hours before harvest. Luciferase assays were
subsequently performed on the cell lysates. The results show that luciferase expression was reduced by 40% upon transfection of pHis-Rasd1
(compare bars I and IV). The suppression of luciferase expression by Rasd1 is dosage-dependent, as increasing amounts of pHis-Rasd1 resulted in
further down-regulation of luciferase expression (compare bars II and III; and bars III and IV). (B) Parallel experiments were conducted by transfecting
different amounts of pNonO-V5 (0, 0.1, 0.2, 1 and 2 mg) into HEK293T cells. The presence of NonO in HEK293T cells results in a slight up-regulation of
luciferase expression of up to 130% (compare bars I and V), and this up-regulation is dosage-dependent (Compare bars II and IV; bars II and V). Next,
pNonO-V5 and pHis-Rasd1 were co-transfected in HEK293T cells to determine if the proteins cooperate to influence CREB’s transactivation functions.
Different amounts of pHis-Rasd1 (0, 0.5, 1 and 2 mg) were co-transfected with pNonO-V5 (2 mg), and cells were treated with forskolin before harvest.
We observed that luciferase expression was reduced by 80% in the presence of both NonO and Rasd1 (compare bars I and VIII). The activation effect
observed when NonO was transfected alone was abolished upon co-transfection of NonO with Rasd1 in the cells (compare bars V with VIII). The
suppressive effect on luciferase expression was further enhanced in the presence of NonO and Rasd1 as compared to that of transfection of Rasd1
alone (compare (A) bar IV and (B) bar VIII). Representative Western blots were included to show the protein expressions of Rasd1 and NonO. Actin was
included as a loading control. Rasd1 is detected with anti-Xpress; NonO is detected with anti-V5; and actin is detected with anti-actin.
doi:10.1371/journal.pone.0024401.g002
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24401Figure 3. GTP hydrolysis activity of Rasd1 is required to cooperate with NonO to suppress CREB’s activity. (A) NonO localises primarily
in the nucleus of HEK293T cells transiently transfected with pNonO-V5 (2 mg) (Figure A2). Rasd1 is distributed throughout the cell in the event of
individual transfection of pHis-Rasd1 (2 mg) (Figure A5). A considerable increase in the amount of Rasd1 was observed to be present in the nucleus
upon the event of co-transfection with pGST-NonO (compare Figures A5 with A8). The sub-cellular location of NonO was unaffected in cells co-
transfected with pHis-Rasd1 (compare Figures A2 with A9). Rasd1 mutants, A178V, G81A, T38N and Del-NLS, display similar cellular distribution to
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studies will be required to decipher the exact mechanism
employed by NonO to enable the enhanced nuclear presence of
Rasd1. Recently, Chuderland et al. identified a novel nuclear
localisation sequence termed the NTS (nuclear translocation
sequence), composed of phosphorylated S/T-P-S/T, that enables
nuclear translocation of the protein via binding to importin 7
[38,39]. This mode of nuclear translocation is used by proteins of
different signaling pathways, including the ERK (extracellular
signal-regulated kinase) pathway, and was initially discovered on
ERK-2 [38,39]. This mode of nuclear entry enables rapid
response to signaling and also adequately explains the increase
in the amount of Rasd1 found in the nucleus in the presence of
NonO. Interestingly, a ‘TPT’ amino acid sequence is found in
Rasd1; this sequence is evolutionarily conserved, and is also
present in Rasd2, a paralog of Rasd1. Further studies are required
to determine if nuclear translocation of Rasd1 requires its ‘TPT’
sequence.
In our study, we observed that NonO only upregulates CREB-
GAL4DBD fusion protein activity slightly via reporter gene assay.
This observation contradicts a previous study, which suggests that
NonO works as a strong co-activator of the cAMP-dependent
pathway via interaction with TORC2, tranducers of the regulated
CREB [13]. In our reporter gene system, the CREB-GAL4DBD
fusion construct used in the assay lacks the bZIP domain. It has
been shown that TORC2 interacts with CREB via the bZIP
domain [40]. Hence, deletion of the bZIP domain in the CREB-
GAL4DBD construct prevents interaction between CREB and
TORC2 [8]. This may serve to explain the minor induction of the
luciferase activity upon transfection of NonO in HEK293T cells.
Many transcription factors, RNA-binding proteins and tran-
scriptional co-regulators are known to be bi- or multi-functional
proteins. Some bi-functional proteins, including CoAA, PGC-1,
CAPERa and CAPERb, and steroid receptors, are shown to be
involved in transcription co-activation and alternative splicing
[15,41,42,43]. Multi-functional proteins like NONO and PSF
(polypyrimidine tract-binding protein-associated splicing factor)
perform RNA processing functions, transcriptional activation and
repression, and RNA transport [12,13,14,15,31,32,33,44,45]. In
addition, NONO is also involved in circadian rhythm as an
antagonist of Per1 [46]. Multiple lines of evidence indicate that
NonO is a multi-tasking protein with bimodal function in
transcription [12,13,14,15,31,32,33,46]. NonO is known to serve
as a co-activator by interacting with TORC2 to up-regulate target
genes of the cAMP-dependent pathway [13]. However, NonO is
also known to repress transcription by recruiting histone
deacetylase (HDAC) to the target promoter by itself or via
interaction with PSF [12,15]. In addition, NonO is known to
interact directly with histone to suppress transcription of prolyl-4-
hydroxylase a1 upon induction of cells with TNFa [15].
Moreover, NonO has been shown to serve as both co-activator
and repressor of androgen receptor-regulated gene transcription
depending on the other proteins associated with the transcriptional
initiation complex [44,45]. Interestingly, another interacting
partner of NonO, DJ-1, has been shown to switch NonO from a
co-repressor to a co-activator for neuroprotection functions [47].
In this study, we show that binding of Rasd1 to NonO signals
NonO to switch from a co-activator to co-repressor mode to
suppress transcription of a subset of the CREB target genes. Our
case is similar to NonO’s regulation of the androgen receptor
where NonO can either activate or repress transcription of the
androgen receptor depending on the proteins associated with it
[44,45]. Since Rasd1 is known to serve as a transcriptional co-
repressor of FE-65 [19], and as an antagonist to the function of
transcription factor, Ear-2, in the repression of Renin’s transcrip-
tion [34]; it is conceivable that Rasd1 might enable NonO to serve
as a transcriptional co-repressor of the CREB signaling pathway.
We observed that co-transfection of pNonO-V5 and pGST-Rasd1
resulted in a substantial increase in the nuclear localisation of
Rasd1. This finding resembles that of Lau et al [19], where co-
transfection of Rasd1 and FE-65 results in an increased nuclear
distribution of Rasd1, and suggests that nuclear translocation of
Rasd1 is required for suppression of target-gene transcription. In
addition, we observed that Rasd1 and NonO co-suppress the
transcription of a subset of CREB target genes. It is intriguing that,
unlike NR4A1 and NR4A2 transcripts, FOS transcription was
unaffected by Rasd1 and NonO. The discrepancy observed might
be attributed to the differences in the mechanisms involved in the
transcriptional regulation of NR4A and FOS. Transcriptional
regulation of FOS takes place at both transcriptional initiation and
elongation processes, which allows an additional level of control of
the FOS gene [48,49,50]. Currently, NR4A proteins are only
known to be regulated by transcription factors at the transcription
initiation stage [13,51,52]. Our study also suggests that Rasd1 and
NonO bind the CRE-site of the NR4A2 promoter to repress its
transcription and that the mechanism employed by Rasd1 and
NonO in the repression of transcription of NR4A genes involves
the regulation of proteins required for the transcription initiation
step. Further studies will need to be performed to explore the
mechanism involved.
Many signal transduction pathways converge in the nucleus
through modulating CREB, whose phosphorylation pattern
influences binding of its co-activators, including CBP/p300 in
the presence or absence of TORC2 [7,8]. Phosphorylation of
CREB by PKA and other kinases of the cAMP signaling pathway
activates CREB to recruit co-activators, other transcription
factors, and general transcription factors to the target promoter,
resulting in the transactivation of target genes [13]. It remains
unclear how CREB is able to converge diverse signals and elicit
differential effects on target gene expression. In the case of the
cAMP-dependent pathway, the co-regulators that interact with
CREB may play an important role for the cell to have a specific
response in different contexts [30]. There are a plethora of CREB
co-regulators, and their activities are known to be regulated by
Rasd1 in the event of single transfection (Figures A 5, 12, 19, 26, and 33). However, co-transfection of plasmids expressing Rasd1 mutants and NonO
did not affect the mutants’ sub-cellular distribution, unlike that of wild-type Rasd1 (compare Figures A5 with A 15, 22, 29, and 36). Likewise, the sub-
cellular distribution of NonO was also unaffected by the presence of Rasd1 mutants, A178V, G81A and Del-NLS (compare Figures A2 with A 16, 23,
and 37). Interestingly, NonO was translocated to the cytoplasm in the presence of T38N (compare Figures A2 with A30). (B) Effects of Rasd1 mutants
on the CREB pathway in the presence of NonO were studied in HEK293T cells. Cells were co-transfected with pNonO-V5 and either Rasd1 or Rasd1
mutants, and luciferase assays were performed after lysis of cells. Cells were induced with forskolin for 4 hours prior to harvesting. The CREB-
mediated transcription was repressed in cells co-transfected with pNonO-V5 (2 mg) and pHis-Rasd1 (2 mg) (Compare Bars II with III). However, the
repressive effect on CREB is abolished in cells transfected with Rasd1 mutants expressing plasmids compared with cells transfected with pHis-Rasd1
(Compare Bars III with IV–VII). ‘*’ – p,0.05; ‘**’ – p,0.01; ‘***’ – p,0.001. (C) Interaction studies of NonO and Rasd1 mutants were studied via co-
transfection of pNonO-V5 and pGST-Rasd1 mutant clones in COS-7 cells. GST-pulldown was subsequently performed and similar to wild-type, only
constructs T38N and A178V were able to interact with NonO (Lanes 2, 3 and 5).
doi:10.1371/journal.pone.0024401.g003
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activator, TORC, that is normally anchored in the cytoplasm by
14-3-3 proteins in the absence of stimulation of the pathway [7,8];
and competition for limiting factor such as CBP, which is a co-
activator required for multiple signaling pathways [9]. In this
study, our findings lend credence to a new mode of regulation of
co-activators of the cAMP pathway – modulation of co-activator
function. We define modulation in the context whereby the
identity of an interacting partner of the co-activator determines the
role of the co-activator in regulation of the target gene upon
induction of the cAMP pathway.
NR4A1 and NR4A2 are clock-controlled genes oscillating in
multiple tissues [53,54] and are CREB-target genes whose
expressions are up-regulated upon activation of the cAMP
pathway [13]. The nuclear orphan receptors 4A (NR4A) subgroup
belongs to the nuclear hormone receptor family and consists of
transcription factors capable of recognising the NGFI-B response
element (NBRE) [55,56,57,58]. NR4A proteins can bind to DNA
as monomers, homodimers and heterodimers [59,60]. Transcrip-
tion factor NR4A2 is an immediate early gene induced by many
external stimuli, including retinoic acid, forskolin, prostaglandin
E2, and dexamethasone [51,56,61,62]. NR4A proteins play
important roles in metabolism and in the pathogenesis of various
diseases including colorectal cancer, Alzheimer’s disease, familial
Parkinson’s disease, schizophrenia, inflammatory arthritis, and
manic depression [51,56,61,63,64,65,66]. In addition, NR4A
proteins also play a crucial part in CREB-dependent neuro-
protection, cell survival and cell transformation of HeLa cells
[52,63,67,68]. Expression of NR4A proteins is up-regulated by the
cAMP pathway for initiation of the survival of HeLa cancer cells
[68]. NR4A proteins are activated via the cAMP pathway through
PGE2 in human colorectal cancer cells [51]. HeLa cells with
reduced levels of NR4A proteins displayed a higher tendency for
cell death through anoikis [68].
Circadian rhythm is an endogenous 24-hour cycle consisting of
an input pathway, master clock, and an output pathway; the
underlying mechanism of rhythmistic control is conserved across
species [69]. The clock regulates biological processes in a temporal
manner by synchronising peripheral oscillators possibly through
glucocorticoids, enabling the adaptation and synchronisation of
hormones, sleep-wake cycles, and daily activities with changing
environmentalcues[69,70,71].Recentfindingshavelinkednutrient
and energy metabolism to circadian rhythm [54,72]. Genes
involved in metabolism such as NR4A family are known to oscillate
in liver and muscle [54]. The circadian rhythm can be modulated
by external signals (light, food, temperature), and these signals are
conveyed through the MAPK and cAMP-signaling pathways
[70,73]. Interestingly, central and peripheral oscillators are sensitive
to entrainment by light (photic) and food (non-photic), respectively
[73,74,75]. The phase-resetting signals provided through food on
peripheral clocks are inhibited by glucocorticoids [76].
Interestingly, expression of NR4A2 and Rasd1 are known to be
repressed and upregulated by glucocorticoids, respectively [17,61].
Evidence provided by Rasd1 knockout mice show that Rasd1 may
be involved in the input pathway of the circadian rhythm by
enhancing photic response and reducing the stimulus provided
from non-photic inputs [77]. This suggests that Rasd1 might
function as the bridging molecule for glucocorticoids to inhibit the
phase-resetting pulses by food on peripheral clocks. Rasd1 may
then work with NonO to repress genes involved in metabolism
activated via the cAMP pathway, which results in selective
repression of a subset of target genes. Hence, modulation of
NR4A1 and NR4A2 expression by Rasd1 and NonO could have a
major impact on the circadian control, and disruption of this
process can give rise to metabolic diseases and cancer development
[78,79,80,81].
Materials and Methods
Plasmid constructs
For information on all primer sequences used for cloning, please
refer to Table S1. Coding sequence of mouse Rasd1 (843 bp) was
amplified from mouse brain cDNA library PACT2 and cloned in
frame via restriction sites KpnI and XhoI into expression vectors –
pcDNA4/HisMax
B (V864-20, Invitrogen, USA, CA), and
pXJGST vector modified from parent plasmid pXJ FLAG [82]
by replacing the FLAG coding sequence with the GST coding
sequence – and designated as pHis-Rasd1 and pGST-Rasd1,
respectively. pHA-Rasd1 was constructed by insertion of a HA-tag
at the 39 end of the coding sequence of Rasd1and cloned into
pcDNA4/HisMax
B via KpnI and XhoI. Mouse clone of NonO (1.4
kb) and its truncated constructs were amplified from MGC-6432
(ATCC, USA, VA), and cloned in frame via restriction sites KpnI
and XhoI into pcDNA3.1/V5-His B (V810-20, Invitrogen, USA,
CA) and pXJGST vectors. PCR-based, site-directed mutagenesis
was used to construct all other mutants of NonO and Rasd1,
which were cloned into pcDNA3.1/V5-His B, pXJGST and
pcDNA4/HisMax
B vectors. For NONO knockdown studies,
NONO-shRNA was constructed by cloning of the oligonucleotide
that targets mRNA of NONO into pSUPER.puro (VEC-PBS-
0007/0008, OligoEngine, USA, WA) vector. The negative
control, Neg-shRNA, was constructed by jumbling up the
sequence of the oligonucleotide that was used for cloning of
NONO-shRNA. Annealed oligonucleotides were cloned in pSU-
PER.puro via BglII and HindIII sites. BLAST was performed to
ensure specificity of NONO-shRNA, and that Neg-shRNA did not
target any non-specific sequences. The annealing process was
performed in the annealing buffer (100mM NaCl and 50mM
Hepes, pH 7.4) in BioRad PCR machine: 90uC for 4min, 70uC for
10min, and ramped to 37uC over a period of 45min, kept constant
at 37uC for 15min, and ramped to 10uC over a period of 45min.
Cell culture and transient transfection
HEK293T (ATCC CRL-11268), PC-12 (ATCC CRL-1721),
and COS-7 (ATCC CRL-1651) cells were cultured as previously
described [26,83]. All transfections were performed the next day
Figure 4. Rasd1 requires full-length NonO to suppress the cAMP pathway in HEK293T cells. (A) Schematic drawing of the locations of
specific domains of NonO protein and its truncated constructs. Q, glutamine-rich region; RRM, RNA-recognition motif; HTH, helix-turn-helix and
highly-charged region; P, proline-rich region. Bipartite NLS is located within HTH. (B) HEK293T cells were transfected with pGST-Rasd1 along with
various constructs of NonO-V5. Lysates were then incubated with MagneGST
TM particles, which enable binding of GST-Rasd1. Only NonOD2-V5 did
not interact with GST-Rasd1 (Lane 4). Anti-V5 and Anti-Xpress were used for detection of LacZ and all truncated clones of NonO; anti-GST was used
for detection of GST-Rasd1. (C) Rasd1 (2 mg) was co-transfected with either NonO or NonO mutants (2 mg) and luciferase assay was performed
subsequently. Neither mutant was able to repress CREB’s activity in the presence of Rasd1 unlike that of wild-type NonO (compare Histograms II with
III and IV). (D) Immunofluorescence studies of NonOD1 and Rasd1 in HEK293T cells. GST-NonOD1 is primarily localised in the cytoplasm (Figure D2). In
the event of co-transfection with GST-NonOD1, His-Rasd1 is localised in the cytoplasm, whereas the sub-cellular distribution of His-Rasd1 was
concentrated in the nucleus in the presence of NonO (compare Figure 3 A8 with Figure 4 D5).
doi:10.1371/journal.pone.0024401.g004
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24401Figure 5. Rasd1 and NonO interact at the CRE-site of the target promoter to repress the transcription of endogenous cAMP target
genes, NR4A1 and NR4A2, but not FOS. (A) Quantitative real-time study was performed to study the effect of over-expression of Rasd1 and NonO
on endogenous CREB-target genes in HEK293T cells. Induction of the cAMP pathway with forskolin (20 mM for 45 minutes) leads to the up-regulation
of cAMP target genes – NR4A1, NR4A2 and FOS (compare the respective Bars I and II of each gene). Co-transfection of plasmids expressing Rasd1 and
NonO in forskolin-induced HEK293T cells leads to the down-regulation of NR4A1 and NR4A2 transcripts (compare the respective Bars II and IV of each
gene). The expression of FOS transcript was not affected by the presence of Rasd1 (compare Bars II and IV of FOS). Expression of YWHAH transcript
was not affected either by treatment of cells with forskolin or in the presence of Rasd1 and NonO, and was shown as a negative control (Bars I–IV of
YWHAH). b-actin was used as an internal control for normalization. On the right are representative western blots showing expression of transfected
NonO and Rasd1 in HEK293T cells. Actin serves as a loading control. NonO is detected by mouse anti-V5; Rasd1 is detected with mouse anti-GST; and
actin is detected with anti-actin. (B) Quantitative real-time study of the effect of Rasd1 and NonO on endogenous genes of NONO-knockdown
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5 cells into each well of a 6-well plate unless
stated otherwise. COS-7 cells were transfected using Lipofectami-
ne
TM 2000 (Invitrogen, USA, CA) according to manufacturer’s
instructions. Calcium phosphate method was employed for
transfection of plasmids into HEK293T cells.
In vitro pulldown assay and mass spectrometry
In vitro affinity pulldown assay using mammalian cell lysates was
conducted to identify novel interacting partners of Rasd1. COS-7
cells seeded on 10cm plates were transfected the next day with His-
Rasd1 (24 mg) or pcDNA4/HisMax
B (24 mg) (negative control)
at 90% confluence. Cells were harvested as previously stated [84].
20 ml of Ni-NTA magnetic agarose beads (Qiagen, USA, CA)
were added to purify His-Rasd1 for 1 hour at 4uC. Beads were
washed according to manufacturer’s instructions. This was fol-
lowed by incubation of His-Rasd1-bound beads with PC-12 lysates
overnight (O/N) at 4uC. After incubation, beads were washed and
bound-proteins were eluted by heating in Laemmli buffer at 95uC
for 10 minutes. Samples were fractionated on 12% SDS-PAGE
acrylamide gel and subsequently stained with Coomassie blue.
Bands of interest were excised by scalpels and cut into 1mm
3
cubes. The cubes were then destained with 50% methanol at room
temperature before digestion was carried out with 10 ng/ml
Trypsin (Promega, USA, WI) O/N at 37uC. Subsequently, 50%
ACN/5% Trifluoroacetic acid was used to extract peptides. The
peptides were then dried under vacuum and cleaned with ZipTipH
C18 (Merck Millipore, USA, MA) according to manufacturer’s
instruction. MALDI-TOF/MS was used to elucidate the identity
of the unknown bands. SwissProt database was used for the
analysis of the peptide spectra obtained. The MALDI/TOF-MS
score obtained for NonO was 199.
GST pulldown in vivo interaction studies
COS-7 cells were co-transfected with plasmids expressing
NonO (2 mg) and Rasd1 (2 mg). Cells were harvested as previously
stated [84]. Interaction studies were performed using Mag-
neGST
TM particles (Promega, USA, WI) according to manufac-
turer’s instructions. Bound proteins were eluted by heating in
Laemmli buffer followed by SDS-PAGE and Western blotting.
Co-immunoprecipitation (co-IP) assay
Co-IP of endogenous proteins was performed by scraping one
10 cm plate of HEK293T cells in 1.5 ml of PBS, followed by
centrifugation at 13,000 rpm for 1 minute. The cells were lysed
with NP40 lysis buffer (1% NP40, 150 mM NaCl, 50 mM Tris-Cl,
pH 8.0, 1% deoxycholic acid, 0.1% SDS, protease inhibitor
(Roche, Switzerland, Basel)) and incubated at 4uC for 20 minutes.
The crude lysate was cleared by centrifugation at 13,000 rpm for
20 minutes at 4uC. Experiment was performed with rProtG
agarose beads (Invitrogen, USA, CA) as previously described [84].
The pre-cleared lysates were incubated with rabbit polyclonal anti-
NMT55/p54NRB IgG (Abcam, UK, Cambridge) or rabbit
control IgG (Abcam, UK, Cambridge; negative control). Co-IP
using mouse brain lysates was performed using goat polyclonal
anti-Rasd1 (Abcam, UK, Cambridge) as described elsewhere [84].
NonO was detected using goat anti-NONO (Abcam, UK,
Cambridge) or rabbit anti-NONO (Santa Cruz, USA, CA).
Reporter gene assay
Effects of Rasd1 and NonO in the CREB signaling pathway
were investigated using PathDetect CREB trans-Reporting System
(Stratagene, USA, CA). PathDetect CREB trans-Reporting System
is a GAL4-dependent reporter gene assay. Factors influencing the
phosphorylation of CREB protein (fused to GAL4-DNA-binding
domain) will be monitored effectively by similar changes in the
luciferase activity. HEK293T cells were transfected withpSV-b-Gal
(b-Galactosidase; internal reporter), pFR-Luc (reporter plasmid
with 5xGAL4 binding site and TATA box as minimal promoter),
and pFA2-CREB (CREB (1–280) fused to GAL4-DNA binding
domain(dbd) trans-activatorplasmid) plusdifferent combinations of
pHis-Rasd1, and pNonO-V5 as indicated in Figure 2. pcDNA3.1/
V5-His B and pcDNA4/HisMax
B served as negative controls for
pNonO-V5 and pHis-Rasd1, respectively. Cells were induced with
20 mM forskolin (Sigma-Aldrich, USA, MO) for 4 hours before
harvesting. Luciferase assay was performed using Luciferase Assay
System (Promega, USA, WI) according to manufacturer’s protocol.
20/20
n Luminometer (Promega, USA, WI) was used to measure
luciferase levels. b-gal levels were measured using b-Gal Enzyme
Assay System (Promega, USA, WI) according to manufacturer’s
protocol. Normalisation of data was performed using luciferase
values of wells transfected with pFC2-dbd (negative control)
construct containing only GAL4-dbd and with no trans-activator
function. All values of empty vectors were set as 1. Statistical
analyses were performed using two-tailed unpaired student’s t-test.
Indirect immunofluorescence
HEK293T and COS-7 cells were transfected as indicated in
Figures 3 and 4, respectively. Experiment was performed as
described previously [19]. Primary antibody incubation was
HEK293T cells. Similar to (A), induction of cells with forskolin leads to the up-regulation of cAMP target genes – NR4A1, NR4A2 and FOS (compare Bars
I with II of each gene). Next, rescue of NONO was performed by transfection of plasmid expressing NonO in NONO-knockdown cells. The transcripts of
NR4A1, NR4A2 and FOS were up-regulated, confirming the involvement of NonO in the regulation of their transcription (compare Bars III with IV of
each gene). In NONO-knockdown cells with over-expression of Rasd1, the transcripts levels of NR4A1, NR4A2 and FOS were comparable to NONO-
knockdown cells (compare bars III and V of each gene). This suggests that Rasd1 requires NONO to repress the transcription of the CREB-target genes.
Repression of target genes, NR4A1 and NR4A2, was observed in NONO-knockdown cells that were co-transfected with Rasd1 and NonO (compare Bars
IV with VI of each gene). The expression of FOS transcript remained unaffected by the presence of Rasd1 (compare Bars IV with VI of FOS), similar to
that in Bar IV of (A). b-actin was used as an internal control for normalization. On the right are representative western blots showing expression of
NonO and Rasd1in HEK293T cells. Actin serves as a loading control. NonO and endogenous NONO are detected by anti-NONO; Rasd1 is detected with
anti-GST; and actin is detected with anti-actin. (C) ChIP was performed using forskolin-treated (20 mM for 15 minutes) HEK293T cell lysates transfected
with either pGST-Rasd1 or pGST (negative control) and incubated with either no antibody control (No AB) or anti-NONO (NONO). Primers targeting
the CRE-site of FOS and NR4A2 promoters were used for subsequent PCR study. The results indicated that in the presence of Rasd1, more NONO was
bound to the NR4A2 promoter (compare Lanes 2 and 3). The amount of NONO bound to the FOS promoter displayed no significant difference with or
without transfection of pGST-Rasd1 (Lanes 5 and 6). I, input; and E, elute. (D) Next ChIP was performed similar to (C) using forskolin-treated HEK293T
cells transfected with His-Rasd1 (Rasd1), empty vector (Vec), or His-Del-NLS (Del-NLS; mutant Rasd1 that does not interact with NonO). The sonicated
lysates were subsequently incubated with Anti-Xpress, and primers targeting the CRE-sites on the FOS and NR4A2 promoters were used for PCR
study. Results indicate that neither Rasd1 nor mutant Rasd1 binds to the FOS promoter (Lanes 5 and 6). On the other hand, Rasd1 but not its mutant,
Del-NLS, specifically binds to the CRE-site of the NR4A2 promoter, suggesting that interaction of Rasd1 and NonO is required to suppress the
transcription of NR4A2 (compare Lanes 2 and 3). I, input; and E, elute.
doi:10.1371/journal.pone.0024401.g005
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USA, CA) and GST-Alexa Fluor 488nm (1:100; Santa Cruz,
USA, CA). After that, samples were incubated with secondary
antibody, goat anti-mouse-Alexa Fluor 568nm (1:200; Sigma-
Aldrich, USA, MO). Cells were subjected to Zeiss LSM510
META confocal microscopy studies.
Reverse transcription and Real time PCR
iScript
TM cDNA synthesis kit (Bio-Rad, USA, CA) was
performed according to manufacturer’s instructions. Quantitative
Real time PCR was carried out using iTaq
TM SYBRH Green
Supermix with ROX (Bio-Rad, USA, CA) according to manu-
facturer’s instructions. Primer sequences used for Real time PCR
were listed in Table S2.
Chromatin immunoprecipitation (ChIP)
Confluent HEK293T cells cultured in 10 cm plates were cross-
linked with Formaldehyde (37% stock) for 15min at 37uC. The
reaction was quenched with 1M glycine for 5min at RT. ChIP was
performed using Protein A agarose/Salmon sperm DNA beads
according to manufacturer’s instructions (Merck Millipore, USA,
MA). Appropriate antibody (2 mg) was added to the pre-cleared
lysates and incubated O/N at 4uC on a rotating platform. This
was followed by phenol-chloroform extraction, and subsequent
PCR was conducted using the relevant primers to study target of
interests (refer to Table S2 and Figure 5, C and D).
Supporting Information
Figure S1 Study of gene expression induced by forskolin in
HEK293T cells. Real time PCR was performed as stated in
Figure 5. Only NR4A1, NRR4A2 and FOS transcripts are
upregulated upon treatment with forskolin (Bars VIII, X and
XIV). b-actin was used as an internal control for normalization.
(TIF)
Table S1 Primer sequences used for construction of vectors for
protein expression and knockdown studies.
(TIF)
Table S2 Primer sequences used for Real time PCR and ChIP
experiments.
(TIF)
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